Antoine Pau started his career at Novartis Pharma in the Business Planning Analysis department (Oncology Business Unit). He then joined Mazars as financial auditor where he worked for three years managing the legal audits of pharmaceutical and biotech companies, as well as investments funds, and also participated in the financial due diligence process for tech companies in the Transaction Services department. He joined Truffle Capital in 2008, where he holds the position of Life Sciences Investment Director. He is also an adjunct lecturer at Sciences Po Paris.
PharmD and ESSEC graduate
Board member of Theradiag (ALTER), Vexim (ALVXM), Biokinesis, Deinobiotics and Abivax